摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]quinoline-6-carboxamide | 590369-83-8

中文名称
——
中文别名
——
英文名称
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]quinoline-6-carboxamide
英文别名
N-[(3r)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide;N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]quinoline-6-carboxamide
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]quinoline-6-carboxamide化学式
CAS
590369-83-8
化学式
C17H19N3O
mdl
——
分子量
281.357
InChiKey
NXZABBDOBVXZPT-INIZCTEOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    527.3±30.0 °C(Predicted)
  • 密度:
    1.26±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    45.2
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • Azabicyclic compounds for the treatment of disease
    申请人:——
    公开号:US20030236270A1
    公开(公告)日:2003-12-25
    The invention provides compounds of Formula I: 1 wherein Azabicyclo is 2 W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1-2 substitutents independently selected from R 3 . These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which &agr;7 is known to be involved.
    本发明提供了式I的化合物: 1 其中Azabicyclo是 2 W是一个六元杂环体系,具有1-2个氮原子,或一个10元双环六六并环体系,在任一或两个环中最多有两个氮原子,前提是该双环六六并环体系的桥上没有氮原子,并且还具有1-2个独立选自R 3 的取代基。 这些化合物可以是药物盐或组合物,可以是纯净的对映异构体形式或外消旋混合物,并且在制药中用于治疗那些已知涉及α7的疾病或状况。
  • SELECTIVE ALPHA-7 NICOTINIC RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM
    申请人:THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    公开号:US20180244653A1
    公开(公告)日:2018-08-30
    In alternative embodiments, provided are selective agonists having a high affinity for the alpha7 nicotinic acetylcholine receptor (α7 nAChR), assays for selectivity of nicotinic receptor subtype and ligand-gated ion channel subtype based on receptor occupation and response, behavioral assessments for reversing cognitive impairment after scopolamine treatment, enhancing memory retention over time, pharmaceutical compositions and formulations and devices comprising them, and methods for making and using them, including characterizing and efficiently assaying them for receptor subtype selectivity. In alternative embodiments, provided are substituted anti 1,2,3-triazoles compounds with high affinity, and selective binding, for the alpha7 nicotine acetylcholine receptor (α7 nAChR), as exemplified by 5-(1-(2-(Piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND1”), 5-((quinuclid-3-yl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND8”) and 3-(4-hydroxyphenyl-1,2,3-triazol-1-yl) quinuclidine (“QND8”). In alternative embodiments, provided are products of manufacture such as pumps, devices, syringes and the like comprising a compound, pharmaceutical composition or formulation as provided herein.
    在另一种实施方式中,提供了对α7尼古丁乙酰胆碱受体(α7 nAChR)具有高亲和力的选择性激动剂,基于受体占据和响应的选择性尼古丁受体亚型和配体门控离子通道亚型的筛选方法,行为评估用于在施用东莨菪碱后逆转认知障碍,随时间增强记忆保留,包括表征和高效筛选受体亚型选择性的制备和使用方法的制药组合物和配方以及包括它们的装置,提供了具有高亲和力和选择性结合的替代抗1,2,3-三唑化合物,例如5-(1-(2-(哌啶-1-基)乙基)-1H-1,2,3-三唑-4-基)-1H-吲哚(“IND1”),5-((喹啉-3-基)-1H-1,2,3-三唑-4-基)-1H-吲哚(“IND8”)和3-(4-羟基苯基-1,2,3-三唑-1-基)喹啉(“QND8”)。在另一种实施方式中,提供了制造产品,例如泵、装置、注射器等,其中包括本文提供的化合物、制药组合物或配方。
  • [DE] HETEROARYLCARBONSÄUREAMIDE<br/>[EN] HETEROARYL CARBOXYLIC ACID AMIDES<br/>[FR] AMIDES D'ACIDE HETEROARYLCARBOXYLIQUE
    申请人:BAYER AG
    公开号:WO2003043991A1
    公开(公告)日:2003-05-30
    Die Erfindung betrifft neue Heteroarylcarbonsäureamide, Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten und zur Verbesserung der Wahrnehmung, Konzentrationsleistung, Lernleistung und/oder Gedächtnisleistung.
    这项发明涉及新的杂环芳香族羧酸酰胺,其制备方法以及它们用于制备用于治疗和/或预防疾病以及改善感知、注意力、学习能力和/或记忆力的药物的用途。
  • Heteroaryl carboxamides
    申请人:Hendrix Martin
    公开号:US20080009624A1
    公开(公告)日:2008-01-10
    The invention relates to novel heteroaryl carboxamides, a process for their preparation, and pharmaceutical compositions containing them. These materials are useful for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.
    该发明涉及新型杂环基羧酰胺、其制备方法以及含有它们的药物组合物。这些材料对于治疗和/或预防疾病以及改善感知、注意力、学习和/或记忆方面非常有用。
  • HETEROARYL CARBOXAMIDES
    申请人:Hendrix Martin
    公开号:US20130144062A1
    公开(公告)日:2013-06-06
    The invention relates to novel heteroaryl carboxamides, a process for their preparation, and pharmaceutical compositions containing them. These materials are useful for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.
    本发明涉及新型杂环基羧酰胺、其制备方法以及含有它们的药物组合物。这些材料可用于治疗和/或预防疾病,以及改善感知、注意力、学习和/或记忆。
查看更多